All In Biotech

Drug Trial Radar · NCT06934252

Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis

A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled, 3-Part Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Subcutaneous Doses of TRB-061 in Healthy Participants and in Patients With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 115 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

115

Planned (sponsor's estimate)

Start

May 2, 2025

Primary completion

Sep 2, 2027

Study completion Feb 29, 2028

Sponsor

Lead sponsor
TRex Bio, Inc.Industry
Sponsor type
Industry
First posted
Apr 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1a/1b randomized, double-blind, placebo-controlled study evaluates the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneously (SC) administered TRB-061 in healthy adults and patients with moderate-to-severe atopic dermatitis (AD). The number of dosing cohorts may be increased or decreased in Part 1 (SAD) or Part 2 (MAD). Part 1 (SAD): Healthy participants receiving single doses of TRB-061 or placebo. Part 2 (MAD): Healthy participants receiving multiple doses (3 doses over 8 weeks) of TRB-061 or placebo. Part 3 (Phase 1b): Participants with moderate-to-severe AD receiving repeated doses (4 doses over 12 weeks) of TRB-061 or placebo.

Conditions

  • Moderate-to-severe Atopic Dermatitis

Interventions

  • TRB-061Drug

    Single subcutaneous injection of TRB-061 at escalating doses

  • TRB-061Drug

    Subcutaneous TRB-061 administered every 4 weeks for a total of 4 doses

  • TRB-061Drug

    Subcutaneous TRB-061 administered every 4 weeks for 3 doses

  • PlaceboDrug

    Single and multiple subcutaneous doses of placebo matching TRB-061 in patients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Screening to Day 85 (SAD), Up to Day 127 (MAD); up to Day 253 (Phase 1b)

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • Alfred Health

    Melbourne, Australia · Recruiting

  • MCR Sunshine

    Saint Albans, Australia · Recruiting

  • Paratus Clinical Research - Canberra Trial Clinic

    Deakin, Australian Capital Territory, Australia · Recruiting

  • Paratus Clinical Brisbane Pty Ltd

    Albion, Brisbane, Australia · Recruiting

  • Paratus Clinical Research Western Sydney

    Blacktown, New South Wales, Australia · Recruiting

  • Paratus Clinical Research Central Coast

    Kanwal, New South Wales, Australia · Recruiting

  • Cornerstone Centre for Clinical Research

    Coorparoo, Queensland, Australia · Recruiting

  • CMAX Clinical Research Pty Ltd

    Adelaide, South Australia, Australia · Active not recruiting

  • Paratus Clinical Research Melbourne

    Melbourne, Victoria, Australia · Recruiting

  • Pacific Clinical Research Network-West Auckland

    Auckland, New Zealand · Recruiting

  • MCR Christchurch

    Christchurch, New Zealand · Recruiting

  • MCR Palmerston North

    Palmerston North, New Zealand · Recruiting

  • Momentum Clinical Research Pukekohe

    Pukekohe, Auckland, New Zealand · Recruiting

  • Momentum Clinical Research Dunedin

    Dunedin, Otago, New Zealand · Recruiting

  • Pacific Clinical Research Network-Tasman

    Nelson, Tasman District, New Zealand · Recruiting

  • Clinical Trials New Zealand Ltd

    Hamilton, Waikato Region, New Zealand · Recruiting

  • Medical Research Institute of New Zealand

    Newtown, Wellington Region, New Zealand · Recruiting

  • Pacific Clinical Research Network-Wellington

    Upper Hutt, Wellington Region, New Zealand · Recruiting

  • Momentum Clinical Research Kapiti

    Waikanae, Wellington Region, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.